Managed Care Thesis Faces Insider Selling Pressure; Merck and J&J Pipeline Advances Provide Partial Offset

Major insider selling by Berkshire Hathaway and David Tepper in UnitedHealth during Q1 2026 contradicts the managed-care leg of the thesis despite bullish sell-side consensus, while recent pipeline wins at Merck and J&J reinforce the diversified pharma component.

What changed

Two significant developments have emerged since the last update, one contradicting and one supporting the thesis:

Insider selling at UnitedHealth: Berkshire Hathaway and David Tepper both reduced their stakes in UnitedHealth Group (UNH) during the same quarter, according to reporting from June 22, 2026. This occurred despite sell-side consensus maintaining a price target of $407.38 and 22 buy or strong buy ratings. UNH closed the snapshot period at $405.81.

Merck pipeline and strategic spending: Merck announced a $50 billion capital allocation plan, with new immunology and vaccine milestones advancing its pipeline. The company also achieved positive Phase 3 results for tulisokibart in ulcerative colitis and met goals in an anti-TL1A antibody study, signaling continued clinical execution.

J&J oncology and medtech wins: Johnson & Johnson's oncology, rare disease, and medtech portfolio has generated analyst commentary highlighting how these wins have "changed its investment story," supporting the thesis's diversified-growth narrative. J&J closed at $240.74.

Analyst support for UnitedHealth: Jim Cramer recommended buying UnitedHealth Group stock on June 24, 2026, and a comparative analysis between UnitedHealth and Humana published June 22 favored UnitedHealth as the better bet, supporting the managed-care thesis despite the insider selling.

Why it matters

Merck's capital deployment and pipeline progress: Merck's $50 billion capital plan and recent Phase 3 wins in immunology (tulisokibart in ulcerative colitis, anti-TL1A antibody) and vaccine milestones reinforce the thesis's pharma leg. The mechanism is that successful late-stage trial data and regulatory approvals reduce execution risk and extend the company's addressable market, supporting the narrative that diversified healthcare companies can grow through both demographic tailwinds and pipeline innovation. Merck's stock price at $120.47 sits below analyst targets according to the thesis narrative, suggesting further upside if these pipeline wins translate to revenue growth and margin expansion.

J&J's oncology and medtech narrative shift: The commentary that J&J's oncology, rare disease, and medtech wins have "changed its investment story" supports the thesis's claim that diversified healthcare companies are attracting upgrades and price target increases. This is material because it broadens the growth narrative beyond managed care into high-margin specialty pharma and medtech, reducing dependence on any single segment and providing multiple paths to outperformance. J&J at $240.74 benefits from this portfolio diversification, which the thesis explicitly highlights as distinct from the GLP-1 coverage story.

Opposing sources and risks

The insider selling by Berkshire Hathaway and David Tepper represents the most material contradiction to the thesis. Both are long-term, fundamental investors with deep healthcare expertise. Their simultaneous reduction of UnitedHealth stakes in Q1 2026 suggests they may perceive:

  • Regulatory or margin pressure: UnitedHealth reached a proposed FTC settlement over insulin rebating practices (reported June 23), which could signal regulatory headwinds that constrain profitability despite demographic tailwinds.
  • Valuation exhaustion: The stock may have already priced in the aging-demographics thesis, leaving limited upside from current levels.
  • Competitive or operational risks: Insiders may see competitive pressures or operational challenges not yet reflected in sell-side models.

The thesis would be invalidated if UnitedHealth's earnings growth materially underperforms Medicare enrollment growth, or if regulatory actions (such as the insulin rebating settlement) significantly compress margins despite rising patient volumes. The divergence between insider selling and analyst bullishness is the key risk to monitor.

What to watch

  1. UnitedHealth earnings and margin trends: Track whether UnitedHealth's next earnings report shows margin compression or guidance cuts that might justify insider selling. If earnings growth accelerates despite insider selling, it would suggest insiders were wrong and the thesis remains intact.

  2. Merck revenue growth from new pipeline wins: Monitor whether tulisokibart and the anti-TL1A antibody generate meaningful revenue contribution and whether the $50 billion capital plan is deployed into acquisitions or R&D that extend the pipeline further.

  3. J&J oncology and medtech revenue acceleration: Track whether J&J's oncology and medtech segments deliver the growth rates implied by analyst commentary, validating the thesis's claim that diversified pharma is a better bet than managed care alone.

  4. Regulatory outcomes for UnitedHealth: The insulin rebating settlement and any future regulatory actions should be monitored for their impact on margins and competitive positioning.

  5. Insider buying or selling patterns: If other large holders (e.g., Vanguard, BlackRock, or other hedge funds) also reduce UnitedHealth stakes, it would strengthen the case that insiders see structural headwinds. Conversely, if insider buying resumes, it would suggest the Q1 selling was tactical rather than strategic.

Related Arbora context

This thesis sits alongside several related theses in the healthcare cluster:

  • GLP-1 and obesity drug coverage expansion (concept-glp1-obesity-drug-coverage): The managed-care thesis is explicitly distinct from the GLP-1 story; however, managed-care companies like UnitedHealth will be major payers for GLP-1 drugs, creating an indirect link. If GLP-1 adoption accelerates and drives higher medical costs, it could pressure managed-care margins, creating a hidden risk to the thesis.

  • Healthcare rotation as AI selloff hedge (concept-healthcare-rotation-ai-selloff-hedge): The recent insider selling at UnitedHealth occurred amid broader healthcare rotation, but the insider action predates the rotation narrative, suggesting the selling was fundamental rather than tactical.

  • Pfizer and large-cap pharma value recovery (concept-pfizer-largecap-pharma-value-recovery) and AbbVie large-cap pharma M&A pipeline build (concept-abbvie-largecap-pharma-ma-pipeline-build): These theses complement the pharma leg of the managed-care thesis, with Merck and J&J pipeline wins supporting the broader large-cap pharma recovery narrative.

Sources

This article is research notes and should not be construed as financial advice.